We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Computer-Aided Detection Overused in Mammography Screening

By HospiMedica International staff writers
Posted on 07 Nov 2017
Despite its limited accuracy, use of computer-aided detection (CAD) continues unabated at digital screening mammography facilities in the United States, according to a new study.

Researchers at the Hospital of Cook County (Chicago, IL, USA) and the University of Nebraska (UNL; Lincoln, USA) accessed the U.S. More...
Food and Drug Administration (FDA) database of certified mammography facilities to generate a random sample list of 400 (out of approximately 8,500) facilities. In 2008 and 2011, a telephone survey was conducted of the facilities regarding digital mammography and CAD use; in 2016, facility websites were reviewed before calling the facilities. The researchers than assessed the proportion of CAD at the digital facilities for the three surveys.

The results revealed that the mean proportion of digital facilities using CAD was 91.4% in 2008, 90.2% in 2011, and 92.3% in 2016. The difference for 2008 versus 2011 was thus 1.3%, while for 2011 versus 2016 it was -2.1%, and for 2008 versus 2016 it was -0.8%. The researchers noted that despite evidence from the Breast Cancer Surveillance Consortium (BCSC) that shows CAD reduces performance by increasing recalls, decreasing the detection of invasive cancer, and increasing the detection of ductal carcinoma in situ (DCIS), its use increased dramatically along with the conversion from film to digital. The study was published on October 6, 2017, in the Journal of the American College of Radiology.

“Although computer-aided detection appeared promising in earlier studies, in our review of the literature, we could not identify recent peer-reviewed journal articles that report results different from the BCSC,” concluded lead author John Keen, MD, of Cook County Hospital. “This persistent utilization is relevant to the debate on the value of targeting DCIS in screening. Using it as an adjunct to radiologist interpretation may be considered the standard of care in a legal setting, thereby further encouraging its use.”

DCIS is the most common type of non-invasive breast cancer, in which the abnormal cells are contained inside the milk ducts. If DCIS is not treated, it may eventually develop into invasive breast cancer, which can spread outside the ducts into the breast tissue and then possibly to other parts of the body. Since DCIS cannot usually be felt as a breast lump or other breast change, most cases are diagnosed following routine screening with mammograms or ultrasound, appearing as micro-calcifications.

Related Links:
Hospital of Cook County
University of Nebraska

Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.